Search - tctmd.com

Displaying 1 - 20 of 52

Sort: Relevancy | Date

News Conference News EuroPCR 2025

Lower MACE Risk With FFR- vs Angio-Guided PCI in AS Patients: FAITAVI

L.A. McKeown

May 22, 2025

News Daily News

Evolut TAVI Shows Promise in Low-risk Bicuspid Patients at 3 Years

Yael L. Maxwell

July 22, 2024

Presentation NY Valves 2024

Halt is Not Relevant

Presenter: Stephan Windecker

June 06, 2024

Presentation NY Valves 2024

SAVR Will Have a Longer Lasting Durability Than TAVR

Presenter: Stephan Windecker

June 06, 2024

Presentation NY Valves 2024

Pro-TTVR: Total TR Resolution Must be a Goal and is a Key Factor Impacting Long-Term Outcomes

Presenter: Stephan Windecker

June 05, 2024

Presentation NY Valves 2024

Global Harmonization of Regulatory Standards

Presenter: Stephan Windecker

June 05, 2024

Presentation TCT 2023

Perspective: How I See the Future for TAVR in Younger Patients With Bicuspid AS

Presenter: Stephan Windecker

October 24, 2023

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

News Conference News PCR London Valves 2022

Big Gains in Function, QoL With Transcatheter TV Replacement: TRISCEND Registry

Shelley Wood

November 28, 2022

Presentation TCT 2022

What Do the Guidelines Say?

Presenter: Stephan Windecker

September 18, 2022

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

Presentation TCT 2021

Evidence-Based Antiplatelet and Antithrombotic Therapy for TAVR

Presenter: Stephan Windecker

November 05, 2021

News Opinion Editor's Corner ESC 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

Shelley Wood

August 19, 2021

News Conference News TVT 2020

Reduced Leaflet Motion After TAVR: No Link to Impaired Hemodynamics, Events

Michael O'Riordan

June 23, 2020

News Conference News TVT 2020

Sapien 3 in Intermediate Risk: Death or Stroke Similar to SAVR at 5 Years

Michael O'Riordan

June 22, 2020

News Conference News TVT 2020

MitraClip Cuts Death, HF Hospitalization Across NYHA Class: COAPT

Michael O'Riordan

June 21, 2020

Presentation TCT 2019

AUGUSTUS ACS: A 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation and an Acute Coronary Syndrome

Presenter: Stephan Windecker

September 26, 2019

Presentation TCT 2019

Has TAVR Become the Default Therapy in Patients With Severe Aortic Stenosis?

Presenter: Stephan Windecker

September 25, 2019

News Conference News EuroPCR 2019

TAVR’s Benefit Across ‘Spectrum of Risk’ Supports Paradigm Shifts, Says EuroPCR Statement

Shelley Wood

May 23, 2019

News Conference News EuroPCR 2019

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Shelley Wood

May 16, 2019

Advertisement

Lower MACE Risk With FFR- vs Angio-Guided PCI in AS Patients: FAITAVI

Evolut TAVI Shows Promise in Low-risk Bicuspid Patients at 3 Years

Halt is Not Relevant

SAVR Will Have a Longer Lasting Durability Than TAVR

Pro-TTVR: Total TR Resolution Must be a Goal and is a Key Factor Impacting Long-Term Outcomes

Global Harmonization of Regulatory Standards

Perspective: How I See the Future for TAVR in Younger Patients With Bicuspid AS

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Big Gains in Function, QoL With Transcatheter TV Replacement: TRISCEND Registry

What Do the Guidelines Say?

What’s Going to Be Hot at ESC 2022?

Evidence-Based Antiplatelet and Antithrombotic Therapy for TAVR

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

Reduced Leaflet Motion After TAVR: No Link to Impaired Hemodynamics, Events

Sapien 3 in Intermediate Risk: Death or Stroke Similar to SAVR at 5 Years

MitraClip Cuts Death, HF Hospitalization Across NYHA Class: COAPT

AUGUSTUS ACS: A 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation and an Acute Coronary Syndrome

Has TAVR Become the Default Therapy in Patients With Severe Aortic Stenosis?

TAVR’s Benefit Across ‘Spectrum of Risk’ Supports Paradigm Shifts, Says EuroPCR Statement

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content